A case of concomitant psoriasis and hidradenitis suppurativa previously unresponsive to the standard treatment is described.

Tildrakizumab therapy was initiated after treatment failure to adalimumab, the only biologic approved for the treatment of moderate-to-severe hidradenitis suppurativa, secukinumab, and guselkumab.

To the best of our knowledge, this is the first reported case on successful treatment of concomitant psoriasis and hidradenitis suppurativa with tildrakizumab.

Further studies in larger cohorts are required to establish conclusions that can be applied to patients with concurrent psoriasis and hidradenitis suppurativa in clinical practice.